MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...

YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a biopharmaceutical company specializing in enzymatic therapies for tissue repair, has launched a Phase III clinical trial for its product EscharEx®, ...

Recent health news covers various topics: a new mpox case in New York, promising results of Ozempic for alcohol use disorder, U.S. impact on global health funding, Robert F. Kennedy Jr.'s health ...

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive ...

Short MDWD slightly under 21.14, target 18.58, stop loss @ 21.2 Check the time stamp on this data. Updated AI-Generated Signals for Mediwound Ltd. (MDWD) available here: MDWD. Type a few symbols and ...

RIDGEFIELD, Conn., Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Chefs' Warehouse, Inc. (NASDAQ: CHEF) (the "Company” or "Chefs'”), a premier distributor of specialty food products in the United States, the ...

Invest in the best stocks under $50 with Interactive Brokers for fast trade execution. You don’t need thousands of dollars in the bank to get started investing. Just $50, or less, can help you ...